Corbus Pharmaceuticals Stock (NASDAQ: CRBP)

Corbus Pharmaceuticals Stock (NASDAQ:CRBP), Trade Ideas

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AEYE

AISP

ANTE

ARHS

AVGR

BENF

BREA

CDMO

CELZ

CERO

CIEN

CMPO

CRBP

DAVE

EHAB

ETWO

GROM

HDSN

HNST

MNMD

NEXI

NWGL

OCEA

OSPN

STVN

SWIN

TPVG

VKTX

VSCO

YEXT

YGMZ

Shares of  HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results.

Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

BURL

DXPE

KIDS

TROX

U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday.

American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday

Cancer-Image by PDPics from Pixabay-

Biotech

Health Care

Financing

General

Corbus Pharmaceuticals announces a $82.2M public offering at $19.00 per share. Explore latest updates on CRB-701 clinical study.

What&#39;s Going On With Cancer-Focused Corbus Pharmaceuticals Stock Today?

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

Omeed Malik, founder and CEO of Farvahar Partners, recently voiced his concerns over the TikTok crackdown bill signed by President Joe Biden, expressing distrust in the bill and its implementation.
What Happened: During CNBC&#8217;s &#8220;Last Call&#8221; on Wednesday, Malik stated, "I really have an issue with what TikTok is doing to society. With all of that said… I don't trust this bill that was passed, and I certainly don't trust the Biden administration to implement it fairly." 
Malik, who had previously vouched for a ban on TikTok and the decoupling of the app from China, explained that the text of the bill was &#8220;way too vague.&#8221; He expressed his worries about the bill&#8217;s broad language, which he fears could be used to target any individual or platform deemed &#8220;subject to the direction of a foreign power.&#8221;
&#8220;I am very concerned about that language because that same language was used against our former president of the United States [Donald Trump] for three years when they called him a Russian asset. Does that mean that Truth Social now should be banned as well? What does it mean for Rumble? Or X?&#8221;
Malik also criticized the outdated social media laws in the country, calling for the removal of legal liability shields from big tech companies and the implementation of antitrust laws to break them up. He urged for a bill of rights around privacy to prevent data misuse by all companies, not just TikTok.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"I really have an issue with what TikTok is doing to society, with all of that said… I don't trust this bill that was passed, and I certainly don't trust the Biden administration to implement it fairly," says <a href="https://twitter.com/RealOmeedMalik?ref_src=twsrc%5Etfw">@RealOmeedMalik</a> on Pres. Biden signing the TikTok crackdown bill. <a href="https://t.co/NmVRZwbri6">pic.twitter.com/NmVRZwbri6</a>
&mdash; Last Call (@LastCallCNBC) <a href="https://twitter.com/LastCallCNBC/status/1783279548429115814?ref_src=twsrc%5Etfw">April 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/entertainment/24/04/38397316/elon-musk-says-morgan-freeman-is-awesome-after-american-actor-says-hes-a-huge-fan-of-tesla-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says Morgan Freeman Is &#8216;Awesome&#8217; After American Actor Says He&#8217;s A Huge Fan Of Tesla CEO: &#8216;What He&#8217;s Done, Nobody Else Has Ever Done&#8217;</a>
Why It Matters: The comment was in response to President <a href="https://www.benzinga.com/news/24/04/38394855/biden-set-to-sign-tiktok-ban-into-law-after-senate-passes-bill-supported-by-gop-democrats">Biden signing the bill</a> that could potentially ban or lead to the sale of TikTok, a popular social media platform owned by Chinese company ByteDance.
The bill, which was passed with a Senate vote of 79-18, gives ByteDance a nine-month window to sell the app or face a national ban. The President also has the option to extend this period by 90 days.
The signing of the bill has sparked controversy and debate. TikTok&#8217;s CEO, Shou Zi Chew, has publicly opposed the legislation, stating, "Make no mistake, this is a ban, a ban on TikTok and a ban on you and your voice." 
The platform has vowed to <a href="https://www.benzinga.com/markets/asia/24/04/38418913/tiktok-fights-back-we-arent-going-anywhere-whats-next-for-users">fight back against the legislation,</a> marking a significant development in the ongoing debate over TikTok&#8217;s Chinese ownership.
Read Next: <a href="https://www.benzinga.com/news/24/04/38349837/elon-musk-agrees-every-american-household-will-have-a-1-000-per-month-home-robot-in-7-years-time?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Agrees Every American Household Will Have A $1,000-Per-Month Home Robot In 7 Years&#8217; Time</a>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of&nbsp;<a target="_blank" href="https://www.benzinga.com/author/benzinga-neuro" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Social Media

Politics

Tech

Expert Slams TikTok Ban Bill As 'Way Too Vague,' Questions Impact On Donald Trump's Truth Social, Rumble And X

Dearborn-based Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), on Wednesday, reiterated its commitment to cutting costs in its EV segment to <a href="https://www.benzinga.com/news/earnings/24/04/38417196/ford-q1-earnings-highlights-automaker-beats-street-estimates-guidance-improves-ev-revenue-falls-84">counter its growing losses</a> and withstanding the ongoing price war. 
What Happened: Ford is eyeing hitting profitability in its EV segment with the launch of its next generation of EVs. However, the launch timeline of these vehicles is currently under wraps. In the meantime, the company is looking to cut costs of the business, CFO John Lawler said during the company&#8217;s first-quarter earnings call on Wednesday. 
&#8220;We&#8217;re going to continue to work on driving every dollar of cost out of the business in the near term,&#8221; he said. 
But revenue over the past several months is dropping faster than the company is able to reduce costs, Lawler conceded, referring to the price war triggered by EV giant Tesla which forced others <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38039584/fords-price-cuts-send-mustang-mach-e-sales-soaring-in-weeks-but-next-decade-will-be">including Ford to cut prices </a>to retain their market share. 
 &#8220;If the pricing stabilizes and we don&#8217;t see these significant reductions continuing across the industry, then I think that you could probably start to see some of those cost reductions flow to the bottom line,&#8221; he said. 
While at the onset of EV adoption customers were willing to pay a premium for an EV, they are now looking for cheaper options, Lawler noted. 
&#8220;We think that prices for EVs are going to normalize around where gas is and the consumers are going to weigh the value proposition of that propulsion choice,&#8221;&nbsp;Lawler said while adding that the company does not see EV prices falling below gas vehicle prices.
Why It Matters: Ford&#8217;s EV segment called &#8220;Model e&#8221; posted an EBIT loss of $1.3 billion in the first quarter, a drastic jump from the EBIT loss of $0.7 billion reported in the corresponding quarter of 2023. 
Revenue, likewise, fell 84% year-on-year to $0.1 billion, partly due to the industry-wide pricing pressure. 
For 2024, Ford expects its EV division to post an EBIT loss between $5.5 billion and $5 billion, widening from the EBIT loss of $4.7 billion recorded last year. 
Image Via Shutterstock
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/mobility" rel="noreferrer noopener">following this link</a>.
Read More:&nbsp;<a href="https://www.benzinga.com/news/24/04/38397845/tesla-will-solve-autonomy-even-if-i-got-kidnapped-by-aliens-tomorrow-says-elon-musk-as-he-reveals-ta" target="_blank" rel="noreferrer noopener">Tesla Will Solve Autonomy ‘Even If I Got Kidnapped By Aliens Tomorrow,&#8217; Says Elon Musk As He Reveals Talks With ‘Major Automaker&#8217; For FSD Licensing</a>

Ford CFO Says EV Price Cuts Bringing Down Revenue Faster Than Company Can Cut Costs; 'If The Pricing Stabilizes...'

Allison 3414 Regional Haul Series&trade; (RHS) and 4000 Series&trade; now available to order as the exclusive fully automatic in International RH and HX Series trucks, respectively.

ALSN

Reported Earlier, Allison Fully Automatic Transmissions Selected For International Truck's Latest S13 Models

Nasdaq provided the Company 60 days to submit a plan to regain compliance with the Rule (the &quot;Plan&quot;).&nbsp; The Company intends to submit its plan of compliance to Nasdaq by June 17, 2024.&nbsp;

HRYU

Reported Earlier, Hanryu Holdings Receives Delinquency Notice From Nasdaq For Late Annual Report Filing

IPOs

RBRK

Reported Earlier, Rubrik Prices Upsized Initial Public Offering Of 23.5M Class A Common Shares At $32/Share

<ul>
<li>Advances Labcorp strategy to launch and scale specialty testing&nbsp;in areas such as oncology and rare diseases</li>
<li>Transaction requires court approval, with confirmation expected on&nbsp;May 6, 2024</li>
</ul>

Laboratory Corporation Of America Holdings

NVTA

Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases

<ul>
<li>Walgreens Specialty Pharmacy combines existing specialty assets, fully integrates AllianceRx and represents the company&#39;s latest step to leverage its neighborhood pharmacies into fast-growing areas of healthcare</li>
<li>Investments include new Gene &amp; Cell Services Pharmacy and Innovation Center</li>
</ul>

Reported Earlier, Walgreens Launches New Gene And Cell Therapy Services, Expands Specialty Pharmacy Offerings

SK Hynix, a key supplier to NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), has reported its first profitable quarter in five, attributing the turnaround to soaring demand for AI chips.
What Happened: The South Korean memory chip manufacturer recorded a net profit of 1.92 trillion South Korean won ($1.39 billion) in the first quarter, a stark contrast to the 2.58 trillion won loss in the same period last year, CNBC <a href="https://www.cnbc.com/2024/04/25/nvidia-supplier-sk-hynix-reverses-losses-in-first-quarter-on-ai-demand.html">reported</a>. This marks SK Hynix&#8217;s first positive income since the third quarter of 2022.
The company attributes its strong performance to the increased sales of AI server products, driven by its leadership in AI memory technology, particularly high-bandwidth memory. This technology is crucial for AI chipsets, such as those used by Nvidia.
The demand for AI chipsets has significantly boosted the high-end memory chip market, benefiting major players like SK Hynix and Samsung Electronics.
See Also: <a href="https://www.benzinga.com/markets/equities/24/04/38368953/jim-cramer-sees-nvidia-as-going-from-star-of-the-show-to-being-the-goat-of-the-game?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Sees Nvidia As Going &#8216;From Star Of The Show To Being The Goat Of The Game&#8217;</a>
SK Hynix plans to meet the increasing demand for AI memory by boosting the supply of HBM3E, the latest generation of high-bandwidth memory for AI. The company also intends to introduce 32GB Double Data Rate 5 products this year to strengthen its position in the high-capacity server DRAM market.
"We will continue to work towards improving our financial results by providing the industry's best performing products at a right time and maintaining the profitability-first commitment," said Chief Financial Officer Kim Woohyun.
Why It Matters: The surge in AI chip demand is a result of the growing adoption of large language models like ChatGPT, which rely on high-performance memory chips to generate human-like responses. This trend has led to a significant increase in the demand for high-performance memory chips, benefiting companies like SK Hynix and Samsung Electronics, according to the report.
SK Hynix&#8217;s financial turnaround comes amid a broader resurgence in the South Korean semiconductor industry. In December, Samsung Electronics and <a href="https://www.benzinga.com/government/23/12/36408195/south-koreas-semiconductor-surge-samsung-and-sk-hynix-shatter-records-with-unprecedented-production">the South Korean semiconductor industry</a> experienced substantial growth, marking a significant rebound in production and shipments.
SK Hynix&#8217;s recent financial success is also tied to its strategic investments in the U.S. semiconductor industry. The company announced plans to invest $3.9 billion in an advanced chip-packaging facility in West Lafayette, Indiana, <a href="https://www.benzinga.com/government/24/04/38089624/nvidia-to-benefit-from-sk-hynixs-new-3-9b-indiana-facility-focused-on-high-bandwidth-memory-chips">to mass-produce high-bandwidth memory (HBM)</a>, crucial for powering NVIDIA GPUs used in AI systems training, like ChatGPT. 
This investment underscores the region&#8217;s growing appeal in the semiconductor sector, fueled by the Biden administration&#8217;s efforts to restore America&#8217;s global standing in chip manufacturing and the incentives from the $53 billion Chips Act.
Read Next: <a href="https://www.benzinga.com/news/24/04/38392548/ups-earnings-show-the-weight-of-170-000-salaries-while-it-learns-to-navigate-shipping-slump?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">UPS Earnings Show The Weight Of $170,000 Salaries While It Learns To Navigate Shipping Slump</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Asia

NVDA

Nvidia Supplier SK Hynix Sees First Profit In 5 Quarters, Credits AI Chip Demand

Whales, the colossal beings of the ocean, are not just a marvel because of their size, but also due to their intriguing behaviors and physiological mysteries. From their unique sleeping patterns to their complex relationships with other marine animals, whales continue to fascinate scientists and ocean lovers alike. Let&#8217;s dive deep and explore some of the most fascinating facts about these fascinating gentle giants you probably didn&#8217;t know!
1. How Whales Sleep
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030418/image-194-1024x585.png" alt="" class="wp-image-307987" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030418/image-194-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030418/image-194-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030418/image-194-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030418/image-194-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030418/image-194.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Whales practice unihemispheric slow-wave sleep which allows them to shut down half of their brains: Image Generated Via Dall-E</figcaption></figure>
Ever wondered how a creature as enormous as a whale catches some Z&#8217;s? Whales have a mesmerizing way of sleeping: they shut down only half of their brain along with the opposite eye. The other half stays awake to help them come up for air and to stay alert for potential threats. This unique sleep method is known as unihemispheric slow-wave sleep.
2. Whales&#8217; Surprising Diet
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030429/image-195-1024x585.png" alt="" class="wp-image-307988" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030429/image-195-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030429/image-195-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030429/image-195-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030429/image-195-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030429/image-195.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Despite their large size, whales eat the smallest of marine life. Image Generated Via Dall-E</figcaption></figure>
Despite their massive size, many whales feed on some of the smallest marine life. Baleen whales, for example, sieve tiny krill and plankton through their baleen plates, consuming up to 4,000 pounds of these tiny creatures each day!
3. The Orca-Humpback Feud
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030437/image-196-1024x585.png" alt="" class="wp-image-307989" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030437/image-196-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030437/image-196-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030437/image-196-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030437/image-196-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030437/image-196.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Orcas and Humpback whales have a long-standing dispute. Image Generated Via Dall-E</figcaption></figure>
It seems there&#8217;s some marine drama! Humpback whales are known to have a particular disdain for orcas, also known as killer whales. Humpbacks will often intervene if they see orcas attacking other marine mammals, sometimes even coming to the rescue of seals or other whales!
See Also: <a href="https://www.benzinga.com/markets/equities/24/04/38384714/whats-going-on-with-trump-media-technology-stock-on-tuesday?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Trump Media &amp; Technology Stock On Tuesday?</a>
4. Beluga Whale Quirks
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030457/image-198-1024x585.png" alt="" class="wp-image-307991" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030457/image-198-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030457/image-198-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030457/image-198-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030457/image-198-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030457/image-198.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Beluga Whales are often referred to as the &#8216;canaries of the sea.&#8217; Image Generated Via Dall-E</figcaption></figure>
Beluga whales, often called the &#8220;canaries of the sea,&#8221; are famous for their wide range of vocalizations. These white whales can mimic a variety of sounds and are known to be especially chatty among their peers.
5. Whales Cannot Breathe Underwater
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030505/image-199-1024x585.png" alt="" class="wp-image-307993" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030505/image-199-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030505/image-199-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030505/image-199-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030505/image-199-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030505/image-199.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Despite living in the seas, whales cannot breathe underwater. Image Generated Via Dall-E</figcaption></figure>
Unlike fish, whales can&#8217;t breathe underwater. They are mammals, just like us, and need to surface regularly to breathe air through their blowholes. This adaptation requires them to have a conscious control over their breathing even while sleeping.
6. Whale Songs
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030510/image-200-1024x585.png" alt="" class="wp-image-307994" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030510/image-200-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030510/image-200-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030510/image-200-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030510/image-200-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030510/image-200.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Whale Songs are known to be haunting yet beautiful. Image Generated Via Dall-E</figcaption></figure>
Some whale species are known for their haunting and beautiful songs, especially the humpback whales. These melodies are complex and often sung by the males in a population. Scientists believe these songs play a role in mating rituals and social bonding.
7. Whales&#8217; Life Span
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030528/image-201-1024x585.png" alt="" class="wp-image-307995" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030528/image-201-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030528/image-201-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030528/image-201-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030528/image-201-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030528/image-201.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Whales have some of the longest lifespans among animals. Image Generated Via Dall-E</figcaption></figure>
Whales have some of the longest lifespans in the animal kingdom. For instance, bowhead whales can live over 200 years, making them one of the oldest living animal species on Earth.
8. Whales Help the Environment
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030532/image-202-1024x585.png" alt="" class="wp-image-307996" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030532/image-202-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030532/image-202-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030532/image-202-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030532/image-202-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030532/image-202.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Whales have a crucial role to play in the marine ecosystem. Image Generated Via Dall-E</figcaption></figure>
Whales play a crucial role in the marine ecosystem. Their feces are rich in iron and nitrogen, which fertilize plankton. More plankton means more carbon dioxide is absorbed from the atmosphere, significantly contributing to the reduction of global warming.
9. The Migration of Whales
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030543/image-203-1024x585.png" alt="" class="wp-image-307997" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030543/image-203-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030543/image-203-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030543/image-203-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030543/image-203-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030543/image-203.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Whales undertake some of the longest migrations among mammals. Image Generated Via Dall-E</figcaption></figure>
Whales undertake some of the longest migrations among mammals, traveling thousands of miles annually to breed and feed. This journey often brings them from polar feeding grounds to tropical breeding grounds.
10. Whales and Sharks
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030551/image-204-1024x585.png" alt="" class="wp-image-307998" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030551/image-204-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030551/image-204-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030551/image-204-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030551/image-204-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25030551/image-204.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Whales rarely have to worry about Shark attacks. Image Generated Via Dall-E</figcaption></figure>
While sharks are often viewed as the ultimate predators, in the open sea, large whales have very few enemies. Healthy adult whales, such as the massive blue whale, rarely have to worry about shark attacks. However, orcas, a type of whale, are known to prey on sharks!
Read Next: <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Q1 Earnings Highlights: EV Giant Misses Wall Street Estimates, Makes Cost Cuts, Invests In AI, Spee</a>

Entertainment

Whales Can't Breathe Underwater Same As Us Yet Manage To Dive Miles Into The Ocean And Even Sleep Peacefully: 10 Reasons Why These Gentle Giants Fascinate Me So Much

<ul>
<li>Hyundai Motor Group to establish&nbsp;mid- to&nbsp;long-term strategies to solidify its position as a leading mobility provider in&nbsp;India</li>
</ul>
&hellip;&nbsp;&nbsp; Hyundai Motor India to establish an annual production system of one million units by 2025; Combined with Kia India, Hyundai Motor Group to be able to annually produce 1.5 million units annually in&nbsp;India
&hellip;&nbsp;&nbsp; Electrification strategy to strengthen leadership in the Indian EV market by expanding EV local production and lineups as well as creating EV ecosystems
<ul>
<li>Executive Chair Chung also had a town hall meeting to share visions and strengthen trust with Hyundai Motor India employees</li>
</ul>
&hellip;&nbsp;&nbsp; Approximately 400 local employees attended the site, while over 3,000 joined through a video connection across all Hyundai Motor sites in&nbsp;India
&hellip;&nbsp;&nbsp; Executive Chair highlighted the Group&#39;s customer-centric philosophy, strategic importance of&nbsp;India&nbsp;as well as electrification strategies and future directions
<ul>
<li>Hyundai Motor Group to continue seek future growth strategies in&nbsp;India, which has emerged as the world&#39;s fifth largest economy and top three automobile markets</li>
</ul>

HYMTF

Hyundai Motor Group's Executive Chair Euisun Chung Visits India To Reinforce Long-Term Mobility Strategies

Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) is set to release earnings results for its first quarter before <a href="https://www.benzinga.com/quote/HON/earnings">the opening bell on April 25, 2024.</a>
Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at $2.17 per share, up from $2.07 per share in the year-ago period. Honeywell is projected to report quarterly revenue of $9.03 billion, up from $8.52 billion in the year-earlier quarter, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Last month, Honeywell disclosed the intention to acquire all outstanding shares of Civitanavi Systems S.p.A.
Honeywell shares fell 0.7% to close at $194.79 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/HON/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Deutsche Bank analyst Nicole Deblase downgraded the stock from Buy to Hold and cut the price target from $227 to $215 on April 16, 2024. This analyst has an accuracy rate of 80%.</li>
<li>Barclays analyst Julian Mitchell maintained an Overweight rating and boosted the price target from $230 to $232 on April 2, 2024. This analyst has an accuracy rate of 76%.</li>
<li>RBC Capital analyst Deane Dray maintained a Sector Perform rating and cut the price target from $210 to $209 on Feb. 2, 2024. This analyst has an accuracy rate of 74%.</li>
<li>UBS analyst Chris Snyder maintained a Sell rating and cut the price target from $185 to $180 on July 28, 2023. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Joshua Pokrzywinski maintained an Equal-Weight rating and increased the price target from $213 to $219 on May 1, 2023. This analyst has an accuracy rate of 74%.</li>
</ul>
Read This Next: <a href="https://www.benzinga.com/news/24/04/38402061/jim-cramer-says-this-energy-stock-is-terrific-calls-caseys-general-stores-a-winner">Jim Cramer Says This Energy Stock Is &#8216;Terrific,&#8217; Calls Casey&#8217;s General Stores A &#8216;Winner&#8217;</a>

Earnings

Price Target

Pre-Market Outlook

Honeywell Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Mark Zuckerberg, the CEO of Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), detailed the company&#8217;s vision for AI development, hinting at a shift from chatbots to more advanced AI &#8216;agents.&#8217;
What Happened: Zuckerberg, during Meta&#8217;s first quarter 2024 <a href="https://seekingalpha.com/article/4685907-meta-platforms-inc-meta-q1-2024-earnings-call-transcript">earnings call</a>, discussed the future of AI, emphasizing the transition from chatbots to AI agents. He explained that these agents would be capable of handling more complex tasks and goals, performing numerous queries to achieve the desired outcome.
&#8220;The next phase for a lot of these things are handling more complex tasks and becoming more like agents rather than just chatbots,&#8221; Zuckerberg said. 
He also highlighted the potential for more sophisticated interactions, especially in business use cases, and the significant role these AI agents could play in guiding users through various processes.
&#8220;An agent is going to do is you give it an intent or a goal, then it goes off and probably actually performs many queries on its own in the background in order to help accomplish your goal,&#8221; said the Meta CEO. 
Zuckerberg expressed confidence in Meta&#8217;s ability to develop leading AI models and reaffirmed the company&#8217;s long-term commitment to AI investment.
Deepwater Asset Management&#8216;s Gene Munster sees Zuckerberg&#8217;s Agentic AI vision as the future, believing in its potential and predicting Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) will follow suit.
&#8220;Look for $AAPL to go after the same Holy Grail,&#8221; Munster said on social media platform X.<a href="https://twitter.com/munster_gene/status/1783255102486196359"></a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Zuckerberg ends the call with his vision of building Agentic AI. These go beyond generative AI that you prompt. They are agents that get things done for you. That could be research a topic, buy something, etc. This is also know as personalized AI, and I&#39;m a big believer in…
&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1783255102486196359?ref_src=twsrc%5Etfw">April 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Q1 Earnings Highlights: EV Giant Misses Wall Street Estimates, Makes Cost Cuts, Invests In AI, Speeds Launch Of New Models</a>
Why It Matters: This announcement comes in the wake of Meta&#8217;s Q1 2024 earnings report, which revealed a <a href="https://www.benzinga.com/news/earnings/24/04/38416273/meta-platforms-q1-earnings-highlights-facebook-owner-beats-estimates-but-guidance-higher-costs-ding">27% year-over-year</a> revenue increase. 
Despite this positive performance, the company&#8217;s stock experienced a <a href="https://www.benzinga.com/news/24/04/38421280/metas-stock-plunge-after-q1-numbers-an-overreaction-to-zuckerbergs-capex-move-says-gene-munster-he-w">17% plunge</a> following Zuckerberg&#8217;s announcement of scaling capex and energy expenses for AI.
Earlier, Zuckerberg had also revealed that <a href="https://www.benzinga.com/news/24/04/38420928/meta-ceo-mark-zuckerberg-more-than-50-of-the-content-people-see-on-instagram-is-now-ai-recommended">over 50% of Instagram&#8217;s content</a> and 30% of Facebook&#8217;s posts are now recommended by AI.
Price Action:&nbsp;Meta shares declined 15.1% after hours to $418.85 after closing 0.52% lower at $493.5 in the regular session, according to data <a href="https://pro.benzinga.com/dashboard">from Benzinga Pro</a>.
Read Next: <a href="https://www.benzinga.com/markets/equities/24/04/38368953/jim-cramer-sees-nvidia-as-going-from-star-of-the-show-to-being-the-goat-of-the-game?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Sees Nvidia As Going &#8216;From Star Of The Show To Being The Goat Of The Game&#8217;</a>
Image Credits &#8211; Shutterstock
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://benzinga.com/apis" target="_blank" rel="noreferrer noopener"></a>

Equities

Global

AAPL

Mark Zuckerberg Shifts Meta's Focus To AI 'Agents' Over Chatbots: Apple To Pursue Similar 'Holy Grail,' Predicts Gene Munster

<ul>
<li>QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy</li>
<li>Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC</li>
<li>Data reaffirms&nbsp;the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types</li>
<li>Meeting scheduled with FDA in June to discuss path to registration filing of ANKTIVA plus checkpoint inhibitors in 2nd- and 3rd-line NSCLC patients whose cancer previously did not respond to checkpoint therapy</li>
<li>$100 million&nbsp;in non-dilutive cash infusion with ANKTIVA approval brings cash-on-hand to approximately&nbsp;$240 million&nbsp;for launch of ANKTIVA in non-muscle invasive bladder cancer (NMIBC)</li>
<li>Company has scheduled a conference call to discuss registration plans for NSCLC, status of ANKTIVA launch readiness for NMIBC, and ANKTIVA as the backbone of our clinical trial pipeline for multiple tumor types</li>
</ul>

IBRX

Immunitybio Announces Results Of Anktiva Combined With Checkpoint Inhibitors In Non-Small Cell Lung Cancer; Schedules Meeting To Discuss Registration Path For ANKTIVA In Lung Cancer With FDA

ASE Tech Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASX#NYSE">ASX</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.10 by 18 percent. This is a 4.65 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $4.243 which missed the analyst consensus estimate of $4.410 billion by 100.00 percent. This is a 100.00 percent decrease over sales of $4.305 billion the same period last year.

Earnings Misses

ASE Tech Holding Co Q1 2024 GAAP EPS $0.08 Misses $0.10 Estimate, Sales $4.243 Miss $4.410B Estimate

BRP Subsidiary Juniper Re Teams Up With ICEYE For Multi-Year Flood And Wildfire Data Collaboration

Chinese EV giant, BYD (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), backed by Warren Buffett‘s Berkshire Hathaway, is set to make a bold move in the luxury EV market with the unveiling of its premium brand&#8217;s first sedan at the Beijing auto show, posing a direct challenge to luxury automakers such as Mercedes-Benz.
What Happened: The Denza Z9GT, BYD&#8217;s new sedan, is the fruit of founder Wang Chuanfu&#8217;s persistence with the brand, Reuters reported on Thursday. This development follows Mercedes-Benz reducing its stake in their joint premium EV venture from 50% to 10%.
The Denza Z9GT will join Denza&#8217;s N7 and N8 SUVs and D9 multipurpose vehicles, all of which have seen increasing sales, contributing to BYD&#8217;s dominance in the EV market.
&#8220;In the past, traditional luxury brands were defined by their logos. Today, luxury for new energy brands are defined by technology,&#8221; said Denza general manager Zhao Changjiang.
However, the luxury vehicle will enter a saturated domestic market amid a price war. Overseas, governments are scrutinizing Chinese EVs, blaming Chinese overcapacity for market flooding.
See Also: <a href="https://www.benzinga.com/markets/equities/24/04/38350014/elon-musk-reacts-to-teslas-pricing-debate-only-a-fool-thinks?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts To Tesla&#8217;s Pricing Debate: &#8216;Only A Fool Thinks ….&#8217;</a>
BYD&#8217;s success is crucial to its goal of competing with global leaders like Toyota and Volkswagen and shedding its image as a low-cost automaker.
The luxury push is also necessary to increase profitability as the price war squeezes the margins of mainstream models. Denza&#8217;s D9 has become the group&#8217;s most profitable model with annual sales of 119,000 units.
Why It Matters: Earlier this year, BYD <a href="https://www.benzinga.com/markets/asia/24/03/37776137/chinas-ev-market-charges-forward-warren-buffett-backed-byd-predicts-50-nev-penetration-as-top-player">predicted a significant shift</a> in the new energy vehicle (NEV) landscape. The company has been focusing on <a href="https://www.benzinga.com/news/24/03/37616662/teslas-chinese-rivals-are-coming-for-the-throat-byd-xiaomi-sharpen-knives-for-all-out-ev-price-war">making EVs more affordable</a> than their gasoline counterparts. 
Recently, <a href="https://www.benzinga.com/markets/asia/24/02/37305779/teslas-china-rival-byd-raises-luxury-game-with-233k-ev-supercar-to-rival-ferrari-and-lamborghini">BYD unveiled its most expensive vehicle to date</a>, a fully electric supercar valued at $233,450, challenging traditional supercar manufacturers like Ferrari NV and Lamborghini. The company also announced its <a href="https://www.benzinga.com/news/24/04/38352429/warren-buffett-backed-byd-names-cybertruck-challenger-shark-with-plug-in-hybrid-system-for-extra-bit">first electric pickup truck</a>, the BYD Shark.
In 2008, Berkshire invested around $230 million in BYD, obtaining 225 million shares and a 20.49% stake in Class H shares. Over time,<a href="https://www.benzinga.com/news/24/02/36904335/warren-buffett-backed-byd-reports-impressive-33-1-yoy-growth-in-january-sales-continues-to-scale-sal"> it has reduced its stake</a> and now holds approximately 87.6 million BYD H Shares, equivalent to a 7.98% stake.
Price Action: On Wednesday, BYD&#8217;s stock BYDDF closed at $25.65, up by 2.05% while its ADR BYDDY closed at $51.21, up by 1.2% on the same day.
Read Next: <a href="https://www.benzinga.com/general/education/24/04/38388530/heres-how-much-warren-buffett-could-have-made-investing-in-tesla?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Here&#8217;s How Much Warren Buffett Could Have Made Investing In Tesla</a>
Photo via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

BYDDF

BYDDY

Warren Buffett-Backed BYD Takes On Luxury EV Market With New Premium Sedan, Posing Direct Challenge For Mercedes-Benz

Spotify Technology SA&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) second attempt to update its iOS app in the EU has been thwarted by Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) due to non-compliance with its App Store rules.
What Happened: The update for <a href="https://www.benzinga.com/markets/equities/24/03/37454551/apple-hit-with-a-1-95b-fine-in-eu-in-spotify-antitrust-case">Spotify&#8217;s app in the App Store</a> has been put on hold as the streaming service failed to adhere to the regulations allowing links to external sites for purchases, <a href="https://appleinsider.com/articles/24/04/24/spotify-second-ios-app-update-attempt-in-eu-fails-to-pass-app-store-review">reported</a> AppleInsider on Wednesday.
Apple has introduced new rules for developers&nbsp;to <a href="https://www.benzinga.com/news/24/03/37507425/from-search-to-flights-google-tweaks-everything-for-eus-digital-markets-act">comply with EU legislation</a>, such as the Digital Markets Act. However, not all apps have followed these guidelines.
Apple has&nbsp;created a Music Streaming Services&nbsp;Entitlement for the EEA storefronts, which&nbsp;allows streaming services to use&nbsp;external links, buttons, and calls&nbsp;to action to direct users to a developer&#8217;s website for purchases&nbsp;outside of Apple&#8217;s In-App Purchase&nbsp;mechanism.
See Also: <a href="https://www.benzinga.com/news/24/04/38368777/apple-planning-soccer-broadcasting-foray-with-fifa-after-major-league-rights-success-report">Apple Planning Soccer Broadcasting Foray With FIFA After Major League Rights Success: Report</a>
The App Review team at Apple sent an email to Spotify, stating&nbsp;that version 8.9.33 of Spotify&#8217;s&nbsp;app was stopped from being published to the App Store. This version of the app was designed&nbsp;for the European Economic Area&nbsp;or EEA storefronts.
&#8220;We note that your current submission includes a call to action to purchase a Spotify subscription on your website. As such, you must accept the terms of the Music Streaming Services Entitlement (EEA) and include the entitlement profile in your app for submission,&#8221; the email read. 
Adding, &#8220;To be clear, this entitlement is required even if your app does not include an external link (nor does it require that you offer an external link). We will, however, approve version 8.9.33 after you accept the terms of the Music Streaming Services Entitlement (EEA) and resubmit it for review.&#8221;
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
It is unclear if the&nbsp;app will be blocked in&nbsp;other territories, but since it&nbsp;is an EEA-specific issue, it&nbsp;should be allowed elsewhere.
Why It Matters: This development comes after Spotify&#8217;s&nbsp;<a href="https://www.benzinga.com/24/04/38388246/spotifys-first-quarter-tells-a-story-of-record-profit-and-an-epic-win">record-breaking first quarter</a>&nbsp;in 2024, where the company reported a 20% year-over-year increase in revenue to 3.64 billion euros. This was attributed to efficient cost-cutting initiatives that also brought significant margin improvements.
Spotify&#8217;s stock, however, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38414644/spotify-stock-sheds-all-gains-after-q1-earnings-but-analysts-are-impressed-with-the">shed all its gains</a> after the first quarter earnings report, but analysts were still impressed with the company&#8217;s performance. J.P. Morgan analyst Doug Anmuth maintained Spotify with an Overweight and raised the price target from $320 to $365.
Photo via Shutterstock
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/news/24/04/38357333/elon-musk-reacts-to-tucker-carlson-saying-theres-ton-of-evidence-that-aliens-live-among-us-with-6000?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts To Tucker Carlson Saying There&#8217;s &#8216;Ton Of Evidence&#8217; That Aliens Live Among Us: &#8216;With 6000 Satellites Orbiting Earth, I Think I Would Know&#8217;</a>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Media

SPOT

Spotify Tries To Push iOS Update In EU Again, Gets Rebuffed By Apple Over App Store Terms

Jeff Bezos shared his unconventional approach to productivity, which involves allowing his mind to wander during meetings. This strategy, he believes, fosters creativity and problem-solving.
What Happened: Bezos, the founder of Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Blue Origin, revealed his unique approach to productivity in a recent episode of the &#8220;Lex Fridman Podcast.&#8221;
Bezos, who is currently the second-richest person globally, <a href="https://www.forbes.com/profile/jeff-bezos/?sh=5ef8713b1b23">according</a> to Forbes, does not adhere to a strict schedule or time blocks for meetings. Instead, he encourages creative thinking by allowing his mind to wander during meetings, which can often extend beyond their planned duration.
"I don't keep to a strict schedule," Bezos said, in an episode first released in December. "My meetings often go longer than I plan for them to, because I believe in [mind] wandering."
 &#8220;A lot of people feel like wandering is inefficient," he added.
He advocates for &#8220;messy meetings&#8221; where ideas are freely exchanged, and there is no set end time. Bezos believes that this approach, which some may consider inefficient, can actually enhance productivity, creativity, and happiness.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Jeff Bezos: Amazon and Blue Origin &#x7C; Lex Fridman Podcast #405" width="500" height="281" src="https://www.youtube.com/embed/DcWqzZ3I2cY?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
"When I sit down a meeting, I don't know how long the meeting is going to take if we're trying to solve a problem," Bezos said. "The reality is we may have to wander for a long time &#8230; I think there's certainly nothing more fun than sitting at a whiteboard with a group of smart people and spit-balling and coming up with new ideas and objections to those ideas, and then solutions to the objections and going back and forth." He added that "a lot of people feel like wandering is inefficient." 
Bezos&#8217;s approach is supported by a 2016 <a href="https://knowablemagazine.org/content/article/mind/2022/science-wandering-mind">study</a> that found allowing the mind to wander can significantly improve creativity. He suggests that taking breaks from a structured routine to let the mind wander can be an effective way to solve problems that seem unsolvable.
See Also: <a href="https://www.benzinga.com/news/24/04/38349837/elon-musk-agrees-every-american-household-will-have-a-1-000-per-month-home-robot-in-7-years-time?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Agrees Every American Household Will Have A $1,000-Per-Month Home Robot In 7 Years&#8217; Time</a>
Why It Matters: Bezos&#8217;s approach to productivity is in line with his innovative thinking and risk-taking, as evidenced by his recent ventures.
In January, it was <a href="https://www.benzinga.com/general/24/01/36578223/jeff-bezos-made-over-7-9-million-an-hour-every-hour-in-2023-in-under-13-minutes-he-brought-in-the-eq">reported</a> that Bezos&#8217;s net worth had increased by $70 billion in 2023, reaching $177 billion. This remarkable growth was attributed to his strategic investments and business decisions.
Bezos&#8217;s financial acumen was further demonstrated in March when he <a href="https://www.benzinga.com/general/24/03/37591221/jeff-bezos-sold-8-5-billion-worth-of-amazon-stock-and-saved-600-million-in-taxes-by-moving-to-florid">sold $8.5 billion worth of Amazon stock</a> and saved $600 million in taxes by relocating to Florida. This move allowed him to redirect a portion of his wealth into Blue Origin, his space exploration venture, showcasing his commitment to innovation and exploration.
Bezos&#8217; net worth has also been a topic of discussion. Despite a <a href="https://www.benzinga.com/news/24/03/37473160/jeff-bezos-overtakes-elon-musk-reclaims-worlds-richest-person-title-as-wealth-soars-to-200b">fierce competition</a> with Tesla CEO Elon Musk, Bezos reclaimed the title of the world&#8217;s wealthiest individual with a net worth of $200 billion.
Read Next: <a href="https://www.benzinga.com/news/24/04/38357333/elon-musk-reacts-to-tucker-carlson-saying-theres-ton-of-evidence-that-aliens-live-among-us-with-6000?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts To Tucker Carlson Saying There&#8217;s &#8216;Ton Of Evidence&#8217; That Aliens Live Among Us: &#8216;With 6000 Satellites Orbiting Earth, I Think I Would Know&#8217;</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Entrepreneurship

Success Stories

AMZN

Jeff Bezos Reveals His Unconventional Approach To Productivity: 'I Believe In Wandering'

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)&#8217;s Vision Pro, despite a reduced sales forecast, has caught the attention of Jim Cramer, who believes the product could revolutionize the industrial sector.
What Happened: Cramer, the host of CNBC&#8217;s &#8220;Mad Money,&#8221; expressed his optimism about the potential of Apple&#8217;s Vision Pro in a recent episode, <a href="https://www.cnbc.com/2024/04/24/cramers-bullish-on-apples-vision-pro-highlights-enterprise-use.html">reported</a> CNBC. 
He suggested that the product, which is currently being marketed as a consumer device, could be repositioned as an enterprise product.
He pointed out that the Vision Pro could be a valuable tool for the industrial sector, especially with the digital twin technology, which allows users to simulate potential changes before implementing them in reality.
See Also: <a href="https://www.benzinga.com/news/24/04/38392548/ups-earnings-show-the-weight-of-170-000-salaries-while-it-learns-to-navigate-shipping-slump?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">UPS Earnings Show The Weight Of $170,000 Salaries While It Learns To Navigate Shipping Slump</a>
&#8220;The construction of factories is the largest business in the world,&#8221; Cramer said. &#8220;If you could cut waste and test out potential changes on the Vision Pro before you put them in reality — and that&#8217;s what&#8217;s known as a digital twin — then I say that $3,500 price tag is way too cheap.&#8221;
Despite a recent report that Apple is reducing its Vision Pro shipment forecast due to a decrease in demand, Cramer remains bullish on the product. 
He highlighted that Apple&#8217;s ability to sell 400,000 units of a $3,500 product, which is still in the process of having software developed for it, is a strong indicator of the product&#8217;s success.
Why It Matters: The Vision Pro has been a subject of interest for Cramer in the past. In June, he <a href="https://www.benzinga.com/markets/equities/23/06/32829441/apple-vision-pro-headset-too-expensive-jim-cramer-explains-why-the-3-499-price-tag-may-not-matte">argued that the steep price tag</a> of the Vision Pro could be justified by its potential to pave the way for more affordable headsets. 
However, in July, he <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/07/33136437/laser-eyes-why-jim-cramer-says-everyone-will-have-apple-vision">dismissed concerns about</a> Apple&#8217;s reduced production forecasts, stating that it wouldn&#8217;t affect the product&#8217;s success.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/04/38416273/meta-platforms-q1-earnings-highlights-facebook-owner-beats-estimates-but-guidance-higher-costs-ding?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta Platforms Q1 Earnings Highlights: Facebook Owner Beats Estimates, But Guidance, Higher Costs Ding Stock</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Jim Cramer Sees Apple's Vision Pro As A Game-Changer For Industrial Sector: '$3,500 Price Tag Is Way Too Cheap'

Vietnamese billionaire Pham Nhat Vuong has announced plans to inject an additional $1 billion from his personal wealth into the Nasdaq-listed electric vehicle (EV) manufacturer VinFast Auto Ltd NASDAQ: VFS).
What Happened: At a shareholders&#8217; meeting of Vingroup, the conglomerate he chairs, Vuong, who directly owns 18% of its shares, expressed his intention to further bolster the investments in VinFast, which has been running at a loss, reported Reuters. 
&#8220;I plan to give VinFast $1 billion from my own pocket,&#8221; Vuong said.
He and Vingroup have already injected $11.4 billion into the company by the end of the previous year.
Vuong, who also serves as the CEO of VinFast, holds a 97% stake in the company through direct ownership and companies under his control. 
Despite the company&#8217;s stock price plummeting from $10 to $2.5 since its initial listing in August, Vuong remains optimistic about the EV market&#8217;s future.
He stated, &#8220;The electric vehicle market will continue to grow, surpassing combustion engine cars. I will not give up on VinFast.&#8221;
VinFast&#8217;s sales challenges have been well-documented, with the company failing to meet its sales targets last year and reporting significant losses. The company&#8217;s financial troubles have been exacerbated by its reliance on sales to associated companies and a declining global EV market.
Despite these challenges, Vuong remains committed to VinFast, with over 70% of the 35,000 cars sold last year going to an electric taxi company, GSM, which he owns. He is also considering listing GSM on the international market if conditions allow.
See Also: <a href="https://www.benzinga.com/markets/equities/24/04/38395098/tesla-unveils-timeline-for-electric-semi-truck-production-first-units-to-external-customers-by-2?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Unveils Timeline For Scaling Up Electric Semi-Truck Production, First Units From New Factory To &#8216;Ex</a>
Why It Matters: The decision by Vuong to invest an additional $1 billion into VinFast comes at a time when the company is facing <a href="https://www.benzinga.com/markets/equities/24/04/38215061/emerging-tesla-challenger-vinfast-faces-sales-challenges-posing-risks-for-vietnam-billionaire-ph">significant sales challenges</a>. The company&#8217;s financial troubles have been amplified by its dependency on sales to associated companies and a declining global EV market. 
The company has accumulated <a href="https://www.benzinga.com/markets/equities/24/04/38238454/vingroups-vinfast-faces-financial-risks-amidst-global-ambitions-with-5-7b-loss-over-past-three-y">losses of $5.7 billion</a> over the past three years, leading to a 38% drop in Vingroup&#8217;s share price since VinFast&#8217;s U.S. listing in August.
Despite these challenges, Vuong&#8217;s commitment to VinFast is unwavering, and his decision to invest an additional $1 billion demonstrates his confidence in the company&#8217;s long-term prospects.
Back in August, VinFast&#8217;s <a href="https://www.benzinga.com/news/23/08/34081685/vinfasts-market-cap-skyrockets-with-20-stock-surge-securing-third-position-after-tesla-and-toyota">market cap skyrocketed</a> with a 20% stock surge, securing the third position after Tesla and Toyota. The company&#8217;s shares soared 20% in the U.S. market, pushing its market capitalization to $191.2 billion. Despite its U.S. operations not being fully operational, the EV boom prompted a buying frenzy among individual investors.
Read Next: <a href="https://www.benzinga.com/news/24/04/38373389/tesla-ceo-elon-musk-takes-swipe-at-waymo-says-cybertruck-might-be-needed-for-robotaxis-in-san-franci?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla CEO Elon Musk Takes Swipe At Waymo, Says Cybertruck Might Be Needed For Robotaxis In San Francisco Amid Vandalism Frenzy</a>
Image Via Shutterstock 
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Emerging Tesla Challenger To Receive Another $1B From Vietnamese Billionaire: 'I Will Not Give Up On VinFast'

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
With patience, some of the most undervalued <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> can create massive wealth.



Look at&nbsp;ACADIA Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/acad-stock-quote/">ACAD</a>), for example. At one point, it traded at 70 cents, as it developed treatment for Parkinson&rsquo;s disease psychosis. Years later, it would hit a high of $45.10 for a win of about 6,300%.&nbsp;



Most recently, and in far less time,&nbsp;CRISPR Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/crsp-stock-quote/">CRSP</a>) exploded from a low of about $40 to a high of nearly $77.50. Even&nbsp;Corbus Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) popped from about $5 to a high of nearly $40 a share in months. All thanks to a positive Phase 1 trial of a potential cancer drug.&nbsp;



The best news it that there&rsquo;s plenty of undervalued biotech stocks with similar potential. In fact, here are three I&rsquo;ve been watching for some time.



<h2>Viking Therapeutics (VKTX)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/medical-tools-tech-therapeutics-300x169.png" alt="An image of a tablet with 'therapeutics' on the screen, a stethoscope and face mask around it"><div>Source: ra2 studio/Shutterstock</div></div>


Viking Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>) already ran from about $8.50 to a recent high of $24.63. But it&rsquo;s still severely undervalued, even with positive trial data on its obesity treatment. After all, when it comes to obesity treatments, the potential is significant.&nbsp;



Look at&nbsp;Eli Lilly&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>), for example. <a href="https://seekingalpha.com/news/4063037-eli-lilly-stock-gains-q4-beats-obesity-drugs">Now trading</a> at $730 a share, it just&nbsp;blew earnings out of the water, thanks in part to obesity drug sales. In fact, sales of its Zepbound treatment&nbsp;<a href="https://seekingalpha.com/news/4063037-eli-lilly-stock-gains-q4-beats-obesity-drugs">soared</a> to $175.8 million in less than a month, according to Seeking Alpha. That was well ahead of the $75 million expected by WaLL Street. 



VKTX could have similar potential. For example, in October, it&nbsp;<a href="https://www.prnewswire.com/news-releases/viking-therapeutics-presents-new-data-from-phase-1-clinical-trial-of-dual-glp-1gip-receptor-agonist-vk2735-in-oral-presentation-at-obesityweek-2023-301959191.html">posted</a> promising data from a Phase 1 study of VK2735, which resulted in weight loss. Furthermore,&nbsp;<a href="https://seekingalpha.com/news/4060945-viking-therapeutics-gains-amid-takeover-speculation">speculation</a> abounds that VKTX could be ta potential takeover target. 



<h2>ADC Therapeutics (ADCT)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063-300x169.png" alt="Pipette adding fluid to one of several test tubes; biotech NVTA Stock"><div>Source: motorolka / Shutterstock.com</div></div>


ADC Therapeutics&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/adct-stock-quote/">ADCT</a>) is a pioneer in the field of antibody-drug conjugates (ADCs). The company&rsquo;s pipeline comprises ADCs in clinical trials for both hematologic and solid tumor cancers. Also, it&rsquo;s undervalued, even after rocketing from about 50 cents to $4.&nbsp;



For one,&nbsp;ADCs have become one of the <a href="https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html">hottest opportunities</a> in biotech, according to Pfizer (NYSE:<a href="https://investorplace.com/stock-quotes/pfe-stock-quote/">PFE</a>) CEO Albert Bourla. That explains the reason&nbsp;PFE just <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen">bought</a> Seagen for $43 billion, and why it wants to&nbsp;<a href="https://www.fiercepharma.com/pharma/jpm24-pfizer-oncology-chief-still-eyes-adc-deals-post-seagen-org-built-speed-and-efficiency">acquire</a> even more ADC companies.&nbsp;



Additionally, ADCT may be a buyout target for a major company. This followed an announcement of a extremely successful trial of a combination treatment to address relapsed follicular lymphoma (the second most common subtype of non-Hodgkin lymphoma),&nbsp;as <a href="https://ir.adctherapeutics.com/press-releases/press-release-details/2023/ADC-Therapeutics-Announces-Initial-Results-from-Investigator-Initiated-Phase-2-Clinical-Trial-Evaluating-ZYNLONTA-in-Combination-with-Rituximab-in-Patients-with-RelapsedRefractory-Follicular-Lymphoma-FL/default.aspx">noted</a> in a company press release.



&ldquo;In this first-ever study evaluating the combination of Zynlonta and rituximab in patients with relapsed or refractory follicular lymphoma, the overall response rate was 96% and the complete response rate was 85%, with a significant number of patients achieving an early response,&rdquo;&nbsp;<a href="https://ir.adctherapeutics.com/press-releases/press-release-details/2023/ADC-Therapeutics-Announces-Initial-Results-from-Investigator-Initiated-Phase-2-Clinical-Trial-Evaluating-ZYNLONTA-in-Combination-with-Rituximab-in-Patients-with-RelapsedRefractory-Follicular-Lymphoma-FL/default.aspx">added</a>&nbsp;Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.



<h2>Intellia Therapeutics (NTLA)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/12/ntla-stock-300x169.jpg" alt="Intellia Therapeutics (NTLA Stock) logo on a smartphone screen."><div>Source: rafapress / Shutterstock.com</div></div>


Finally, we have&nbsp;Intellia Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ntla-stock-quote/">NTLA</a>), a gene editing company. It just saw its closest competitor, CRISPR Therapeutics, explode on U.S. Federal Drug Administration (FDA) approval of its Sickle Cell Anemia treatment.&nbsp;



Currently sitting at triple-bottom support, NTLA is wildly undervalued, with a good deal of upside potential. Further,&nbsp;<a href="https://thefly.com/news.php?symbol=NTLA">Cathie Wood&rsquo;s Ark Invest</a> just bought 131,000 NTLA shares, now owning 11% of the shares outstanding.&nbsp;



Also, the company recently announced the publication of positive interim Phase 1 data for NTLA-2002 in patients with hereditary angioedema in&nbsp;The New England Journal of Medicine. 



&ldquo;The interim NTLA-2002 clinical data published suggest that a single dose of NTLA-2002 may eliminate angioedema attacks for people suffering from hereditary angioedema,&rdquo;&nbsp;said Intellia President and CEO&nbsp;<a href="https://finance.yahoo.com/news/intellia-therapeutics-announces-publication-positive-220000512.html">John Leonard</a>, M.D.



Lastly, the company is&nbsp;on track to initiate a <a href="https://finance.yahoo.com/news/intellia-therapeutics-announces-publication-positive-220000512.html">global pivotal study</a>&nbsp;for NTLA-2002 in the second half of this year. Therefore, undervalued shares of NTLA have solid catalysts moving forward.



On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/the-3-most-undervalued-biotech-stocks-to-buy-in-february-2024/">The 3 Most Undervalued Biotech Stocks to Buy in February 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Editor&rsquo;s note: &ldquo;How the Medical Industry Could Produce the Biggest AI Stock Winners&rdquo; was previously published in January 2024. It has since been updated to include the most relevant information available.



Most of Wall Street&rsquo;s AI-related headlines have been centered around chipmakers like Nvidia (<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) and software companies like Microsoft (<a href="https://investorplace.com/stock-quotes/msft-stock-quote/">MSFT</a>). But the biggest AI stock boom is happening in an entirely different sector. And it&rsquo;s going unnoticed by the mainstream media.



We&rsquo;re talking about <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>.



In just over four months, the SPDR S&amp;P Biotech ETF (<a href="https://investorplace.com/stock-quotes/xbi-stock-quote/">XBI</a>) has soared more than 55%. And certain biotech stocks have soared much more. Year-to-date, Elevation Oncology (<a href="https://investorplace.com/stock-quotes/elev-stock-quote/">ELEV</a>) is up more than 800%. Skye Bioscience (<a href="https://investorplace.com/stock-quotes/skye-stock-quote/">SKYE</a>) is up more than 500%, and Corbus Pharmaceuticals (<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) is up about 500%.



<a href="https://investorplace.com/wp-content/uploads/2024/03/biotech-ytd-performance.png"><img src="https://investorplace.com/wp-content/uploads/2024/03/biotech-ytd-performance-300x182.png" alt="" width="588" height="357"></a>Why the huge breakout in biotech?



In part, it&rsquo;s thanks to AI.



AI&rsquo;s application in biology holds the potential to unlock enormous economic value for one simple reason: data.



The more data, the better the AI.



It&rsquo;s that simple.&nbsp;



And when it comes to the human body, there is no dearth of quality data. In fact, there is more high-quality data than anywhere else on Earth.



Humans &ndash; like computers &ndash; are really nothing more than a bunch of data strung together.



At their core, computers are just a bunch of 1s and 0s coded in sequence, with each number corresponding to a certain action for the computer to perform. Humans, similarly, are a bunch of As, Gs, Cs, and Ts strung together &ndash; or the four base types found in human DNA molecules &ndash; with each determining a person&rsquo;s characteristics, traits, and even actions.



<a href="https://investorplace.com/wp-content/uploads/2023/05/chromosome-dna-gcats.png"><img src="https://investorplace.com/wp-content/uploads/2023/05/chromosome-dna-gcats.png" alt="" width="736" height="275"></a>Humans are full of data.



Apply AI to all that data, <a href="https://secure.investorplace.com/?cid=MKT788713&amp;eid=MKT794612&amp;step=start&amp;plcid=PLC204443">and you will change the world.</a>







<h2>The AI Revolution Applied to Medicine</h2>



The human body is the greatest mystery of the modern world. AI can solve that mystery, and in so doing, solve myriad problems that plague all humans.



Consider this: It takes about $900 million and 13.5 years to develop a new successful drug.



The drug development process is so expensive and time-consuming that firms cannot afford to push that many drugs forward. This creates a huge shortage in drug candidates and programs relative to what is possible given all the permutations of human biological data.



But AI can significantly shorten and cheapen this process.



Why does it take so long to find new drugs? Because the universe of biological data is enormous. It takes scientists great effort to sort through all the data, uncover the root causes of diseases, and formulate compounds to fight those diseases.



But AI can automate that entire process. It can map out genetic data, identify mutations, and run simulations to find the right compounds and combat those mutations &ndash; all almost instantly. 



Essentially, researchers can use AI to find new drug candidates much faster than is currently possible.



And this is already happening.



Last year, Japanese pharma giant Takeda Pharmaceutical (<a href="https://investorplace.com/stock-quotes/tak-stock-quote/">TAK</a>) bought an experimental psoriasis drug for $4 billion &ndash; a drug that was created in only six months by using AI.



It isn&rsquo;t alone.



Other pharma giants like Bayer, Roche, Sanofi (<a href="https://investorplace.com/stock-quotes/sny-stock-quote/">SNY</a>) and AstraZeneca (<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>) are actively using AI technology for drug discovery purposes.



The future of AI-powered drug discovery starts now.



<a href="https://secure.investorplace.com/?cid=MKT788713&amp;eid=MKT794612&amp;step=start&amp;plcid=PLC204443">This is big business.</a>







<h2>The Final Word</h2>



Research firm Deep Pharma Intelligence estimates that investments in the field of AI-powered drug discovery have tripled over the past four years to nearly $25 billion. 



Morgan Stanley believes this tech will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!



<div><img src="https://investorplace.com/wp-content/uploads/2023/08/ai-drug-development-300x152.png" alt="Cumulative investment in AI drug development" width="624" height="316"><div>Source: Deep Pharma Intelligence</div></div>In other words, a $50 billion AI drug discovery revolution starts now.



Is your portfolio positioned for it? 



<a href="https://secure.investorplace.com/?cid=MKT788713&amp;eid=MKT794612&amp;step=start&amp;plcid=PLC204443">If not, check out a few of the top AI biotech stocks that we are watching right now.</a>



On the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article.



P.S. You can stay up to speed with Luke&rsquo;s latest market analysis by reading our Daily Notes! Check out the latest issue on your&nbsp;<a href="https://investorplace.com/innovationinvestor/">Innovation Investor</a>&nbsp;or&nbsp;<a href="https://investorplace.com/earlystageinvestor/">Early Stage Investor</a>&nbsp;subscriber site.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/hypergrowthinvesting/2024/03/how-the-medical-industry-could-produce-the-biggest-ai-stock-winners/">How the Medical Industry Could Produce the Biggest AI Stock Winners</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

How the Medical Industry Could Produce the Biggest AI Stock Winners

Corbus Pharmaceuticals (CRBP) has issued an announcement. Discover the latest financial performance insights with our current report, which present...

Corbus Pharmaceuticals Shares Informal Financial Snapshot

Corbus Pharmaceuticals files for $300M mixed shelf offering

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Editor&rsquo;s note: &ldquo;How the Medical Industry Could Produce the Biggest AI Stock Winners&rdquo; was previously published in March 2024. It has since been updated to include the most relevant information available.



A bulk of the AI-related headlines that dominate the mainstream media have been centered around software developers and their AI assistants, like OpenAI&rsquo;s ChatGPT and Microsoft&rsquo;s (<a href="https://investorplace.com/stock-quotes/msft-stock-quote/">MSFT</a>) Copilot. But the biggest AI stock boom is happening in an entirely different sector. And for the most part, it&rsquo;s gone largely unnoticed.



We&rsquo;re talking about <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>.



Between early November 2023 and late February 2024, the SPDR S&amp;P Biotech ETF (<a href="https://investorplace.com/stock-quotes/xbi-stock-quote/">XBI</a>) soared more than 55%. And certain <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> have soared much more.



Year-to-date, Elevation Oncology (<a href="https://investorplace.com/stock-quotes/elev-stock-quote/">ELEV</a>) is up more than 700%. Skye Bioscience (<a href="https://investorplace.com/stock-quotes/skye-stock-quote/">SKYE</a>) is up more than 380%, and Corbus Pharmaceuticals (<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) is up about 570%.



<a href="https://investorplace.com/wp-content/uploads/2024/03/biotech-ytd-performance.png"><img src="https://investorplace.com/wp-content/uploads/2024/03/biotech-ytd-performance.png" alt=""></a>Why the huge breakout in biotech?



In part, it&rsquo;s thanks to AI. And considering that this powerful emerging technology is still in its infancy, we think there&rsquo;s a ton of room for these stocks to run.







<h2>It&rsquo;s All About the Data</h2>



AI&rsquo;s application in biology holds the potential to unlock enormous economic value for one simple reason: data.



The more data, the better the AI.



And when it comes to the human body, there is no dearth of quality data. In fact, there is more high-quality data than anywhere else on Earth.



That&rsquo;s because, like computers, humans are really nothing more than a bunch of data strung together.



At their core, computers are just a bunch of 1s and 0s coded in sequence, with each number corresponding to a certain action for the computer to perform. Humans, similarly, are a bunch of As, Gs, Cs, and Ts strung together &ndash; or the four base types found in human DNA molecules &ndash; with each determining a person&rsquo;s characteristics, traits, and even actions.



<a href="https://investorplace.com/wp-content/uploads/2023/05/chromosome-dna-gcats.png"><img src="https://investorplace.com/wp-content/uploads/2023/05/chromosome-dna-gcats.png" alt=""></a>Humans are full of data.



Apply AI to all that data, <a href="https://secure.investorplace.com/?cid=MKT788713&amp;eid=MKT794612&amp;step=start&amp;plcid=PLC205362">and you will change the world.</a>



<h2>Revolutionizing Medicine With AI</h2>



The human body has proven to be quite a complex thing. There&rsquo;s certainly no scarcity of illness or disease that impact folks around the world. And while humanity has made great strides in discovering treatments and cures, countless afflictions remain a reality. 



But AI has the potential to solve the myriad problems that plague all humans.



Consider this: It takes about $900 million and 13.5 years to develop a new successful drug.



The drug development process is so expensive and time-consuming that firms cannot afford to push that many drugs forward. This creates a huge shortage in drug candidates and programs relative to what is possible given all the permutations of human biological data.



But AI can significantly shorten and cheapen this process.



Why does it take so long to find new drugs? Because the universe of biological data is enormous. It takes scientists great effort to sort through all the data, uncover the root causes of diseases, and formulate compounds to fight those diseases.



But AI can automate that entire process. It can map out genetic data, identify mutations, and run simulations to find the right compounds and combat those mutations &ndash; all almost instantly. 



Essentially, researchers can use AI to find new drug candidates much faster than is currently possible.



And this is already happening. 



Last year, Japanese pharma giant Takeda Pharmaceutical (<a href="https://investorplace.com/stock-quotes/tak-stock-quote/">TAK</a>) bought an experimental psoriasis drug for $4 billion &ndash; a drug that was created in only six months by using AI.



It isn&rsquo;t alone.



Other pharma giants like Bayer, Roche, Sanofi (<a href="https://investorplace.com/stock-quotes/sny-stock-quote/">SNY</a>) and AstraZeneca (<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>) are actively using AI technology for drug discovery purposes.



The future of AI-powered drug discovery starts now.



<a href="https://secure.investorplace.com/?cid=MKT788713&amp;eid=MKT794612&amp;step=start&amp;plcid=PLC205362">This is big business.</a>







<h2>The Final Word</h2>



Research firm Deep Pharma Intelligence estimates that investments in the field of AI-powered drug discovery have tripled over the past four years to nearly $25 billion. 



Morgan Stanley believes this tech will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!



<img src="https://investorplace.com/wp-content/uploads/2023/08/ai-drug-development.png" alt="">In other words, a $50 billion AI drug discovery revolution starts now.



Now, of course, AI&rsquo;s applications in healthcare aren&rsquo;t limited to discovering viable drug candidates. 



In fact, this week, March 18-21, 2024, Nvidia (<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) is holding its GPU Technology Conference (GTC), an event for AI developers and enthusiasts. And the tech titan revealed that it&rsquo;s partnering with Johnson &amp; Johnson (<a href="https://investorplace.com/stock-quotes/jnj-stock-quote/">JNJ</a>). The two will develop AI to help doctors perform surgery. 



This is a huge development. After all, according to Nvidia, &ldquo;J&amp;J MedTech is in 80% of the world&rsquo;s operating rooms and trains more than 140,000 healthcare professionals each year.&rdquo; It&rsquo;s very likely that within the next decade, almost all surgeries will be at least partially automated by AI.



The potential that artificial intelligence holds for the healthcare industry is enormous. And as such, it&rsquo;s high time to bulk up your portfolio with top-of-the-line <a href="https://investorplace.com/industries/technology/artificial-intelligence/">AI stocks</a>.



<a href="https://secure.investorplace.com/?cid=MKT788713&amp;eid=MKT794612&amp;step=start&amp;plcid=PLC205362">Discover which high-octane stocks we&rsquo;re piling into.</a>



On the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article.



P.S. You can stay up to speed with Luke&rsquo;s latest market analysis by reading our Daily Notes! Check out the latest issue on your&nbsp;<a href="https://investorplace.com/innovationinvestor/">Innovation Investor</a>&nbsp;or&nbsp;<a href="https://investorplace.com/earlystageinvestor/">Early Stage Investor</a>&nbsp;subscriber site.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/hypergrowthinvesting/2024/03/how-the-medical-industry-could-produce-the-biggest-ai-stock-winners/">How the Medical Industry Could Produce the Biggest AI Stock Winners</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
What has been the top-performing stock so far of 2024?



If you had said server installer Super Micro Computer (NASDAQ:<a href="https://investorplace.com/stock-quotes/smci-stock-quote/">SMCI</a>), that would be a great answer. Louis Navellier&rsquo;s AI bet has surged 260% this year over AI excitement. Sezzle (NASDAQ:<a href="https://investorplace.com/stock-quotes/sezl-stock-quote/">SEZL</a>) would have been an even better response. This fintech startup has risen 280% since January.



But among large companies, the biggest winner has been Viking Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>), a firm that&rsquo;s surged 360% since the start of the year. The company is developing a new weight-loss drug, and initial studies suggest it could be even more effective than current solutions. William White <a href="https://investorplace.com/2024/03/why-is-viking-therapeutics-vktx-stock-up-24-today/">covers the news</a> for InvestorPlace.com, our free news site.



Meanwhile, many small-cap healthcare firms have done even better. Elevation Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/elev-stock-quote/">ELEV</a>) is an early stage cancer research firm that has seen shares surge 840%. In fact, 12 of the top 20 stock performers this year (including small caps) are either biotech or pharmaceutical firms.



That&rsquo;s because biotech firms can be incredible bets. These small firms often have multibillion-dollar therapies in their pipelines&hellip; and the public only learns about them when clinical trial data is finally published.



Fortunately, these types of companies leave &ldquo;clues&rdquo; about their potential success. Medical experts and corporate insiders often know how clincial trials are unfolding well before the public is aware, and it turns out that following (legal) insider trades is one of the best ways to outperform. Corbus Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) &ndash; the fourth-best performer this year &ndash; has seen almost $50 million of insider purchases since January.



That&rsquo;s why I&rsquo;m excited to share Luke&rsquo;s most recent work. Over the past several months, he and his team have come up with a quantitative method to detect these types of biotech winners before they break out. He&rsquo;s already identified a small group of six plays in a biotech subsector that he believes could be the biggest winners. (<a href="https://secure.investorplace.com/?cid=MKT793950&amp;eid=MKT798792&amp;step=start&amp;plcid=PLC205880&amp;SNAID=%%SNAID%%&amp;email=%%emailaddr%%&amp;encryptedSnaid=%%ENCRYPTEDSNAID%%&amp;emailjobid=%%jobid%%&amp;emailname=%%emailname_%%">Get the full details here</a>).



In the meantime, our writers at InvestorPlace.com and I have also been researching top <a href="https://investorplace.com/industries/healthcare/">healthcare stocks</a> to buy. To get you started, here&rsquo;s what we&rsquo;ve found:



<h2>5 Healthcare Stocks to Buy for 2024: Nuvectis (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/cancer-300x169.jpg" alt="A variety of pills, pill bottles, and droppers arranged on a table in multiple bright colors."><div>Source: Shutterstock</div></div>Shares of biopharmaceutical firm Nuvectis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) soared 200% after going public at $5 per share in 2022. Chris MacDonald noted at the time that <a href="https://investorplace.com/2022/02/nvct-stock-alert-7-things-to-know-as-nuvectis-pharma-soars-200/">the intriguing oncology company</a> was an exciting bet on a novel cancer-beating therapy:




The company&rsquo;s key drug candidates include NXP800, a clinical-stage HSF1 pathway inhibitor. This drug is undergoing a Phase 1 study in patients with advanced tumors. This drug, along with NXP900, a preclinical SRC/YES1 kinase inhibitor, are ones that have a more speculative growth trajectory, given their early-stage status.




Fast forward two years, and Nuvectis has seen a sudden string of good news. In February, the U.S. Food and Drug Administration (FDA) granted the NXP800 development program both Fast Track and Orphan Drug designations. The following month, Nuvectis would report positive preliminary data for its Phase 1b clinical trial.



Perhaps the best news has been a recent $50,000 share purchase made by CEO and Chairman Ron Bentsur four days after the Phase 1b results were announced. On March 18, the 10% owner added 5,000 shares to his existing 3.2 million stake.



That&rsquo;s an incredibly bullish sign. The company&rsquo;s Phase 1b trials only included four patients, and the preliminary data is scant at best; only insiders like Bentsur would have full knowledge of efficacy. And the fact that he is adding even more to his already sizable stake suggests Bentsur knows something that markets do not.



That tells us that Nuvectis could be worth a small wager. I&rsquo;ve found <a href="https://investorplace.com/2021/11/5-cheap-stocks-set-to-double-this-month/">other 10x biotech winners before</a> based on these types of insider buys, and Nuvectis looks much like these past bets.



<h2>Eli Lilly (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div>In January, my MarketMasterAI stock-picking system ranked Eli Lilly (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>) as <a href="https://investorplace.com/2024/01/marketmasterai-top-500-stocks-january-2024/">the top healthcare company to buy</a>. The pharmaceutical giant came in seventh place overall.



Since then, shares of the Indiana-based firm have risen 30% on growing excitement over its GLP-1 weight loss drugs Zepbound and Mounjaro. Sales of the latter already exceeded $5 billion in 2023, and demand is so red-hot that shortages are expected throughout 2024.



Last Sunday, Dmytro Spilka wrote that Eli Lilly might now become the <a href="https://investorplace.com/2024/03/the-1-trillion-question-will-lly-tsmc-or-tsla-be-wall-streets-next-nvidia/">world&rsquo;s first trillion-dollar pharmaceutical company</a>. Zepbound, which was made available in December, recorded $175.8 million in sales within a month, smashing through analysts expectations of $75 million. And if profits continue rising at their current rate, Eli Lilly could reach that milestone as soon as this year.



Muslim Farooque goes even further and plainly calls Eli Lilly a name <a href="https://investorplace.com/2024/03/wall-streets-favorite-growth-stocks-7-names-that-could-make-you-filthy-rich/">that could make you filthy rich</a>.




A look at its spectacular Q4 results shows the incredible impact of its anti-obesity drugs on its top-line results. Q4 sales were at $9.35 billion, an extraordinary 28% increase YOY. Its anti-obesity offering in Mounjaro contributed $2.2 billion during the quarter, representing about 25% of total sales. Moreover, Zepbound, its latest weight-loss injection, generated $175.8 million in its debut quarter, with more growth expected ahead.




In short, Eli Lilly and its competitor Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) are sitting on a type of therapy that comes around only once every couple of generations. Around two-fifths of adults are overweight or obese globally, and that figure is as high as 60% in developed countries. Not only does this &ldquo;miracle weight loss drug&rdquo; work well &ndash; its market is absolutely enormous.



<h2>Schrodinger (SDGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/pill-bottle-biopharma-biotech-1600-300x169.jpg" alt="Brown glass pill bottle on its side showing white pills inside, with other pill bottles behind it representing MACK stock."><div>Source: shutterstock.com/Champhei</div></div>Alex Sirois flags Schrodinger (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdgr-stock-quote/">SDGR</a>) as a stock to buy. The software research firm is <a href="https://investorplace.com/2024/03/shhh-7-small-cap-stocks-that-can-double-by-2025/">part biotech stock and part AI stock</a>.




In order to develop a therapeutic, biotechnology firms first have to identify molecules that have the potential to treat a target disease. It&rsquo;s a painstaking process that is becoming easier through the use of computers, machine learning, and artificial intelligence.



Schrodinger has emerged as a leading name in that space. The company essentially does two things. One, it licenses its technology to firms wishing to discover molecules with treatment potential. Two, the company is also currently building a portfolio of clinical and preclinical programs.




Schrodinger has seen significant real-world success. Sirois notes that Q4 revenues grew by more than 30%, and that Schrodinger itself maintains an ability to produce a blockbuster drug of its own. Advances in AI computing power also gives the chemical simulation firm a new edge.



Of course, Schrodinger isn&rsquo;t the only company involved in AI-related drug discovery. But Schrodinger&rsquo;s early start, rising revenues and deep pockets allows it to pour resources into research and development (R&amp;D) in a way that many competitors simply cannot. Analysts expect Schrodinger to spend over $200 million on R&amp;D this year, almost 95% of its revenues.



Luke Lango wrote about this company <a href="https://investorplace.com/2021/09/one-stock-to-dominate-biotech/">as early as 2021</a>. Accelerating growth and improving technologies suggest now could be an ideal time to revisit this moonshot bet.



<h2>IBB and XBI </h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>Finally, investors seeking a big-picture investment should read Eric&rsquo;s latest report on the <a href="https://investorplace.com/smartmoney/2024/03/two-different-flavors-of-biotech/">Two Different Flavors of Biotech</a>. In it, he explains why both the blue-chip iShares Biotechnology ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/ibb-stock-quote/">IBB</a>) and the riskier SPDR S&amp;P Biotech ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/xbi-stock-quote/">XBI</a>) are bets worth taking.



In the case of the former, more conservative pick:




Many of the biggest pharmaceutical companies in the world are paying tens of billions of dollars to snap up promising, albeit profitless, biotech companies. You could call it a biotech gold rush.



Presumably, the &ldquo;crazy&rdquo; prices major pharmaceutical companies are paying to acquire early-stage biotech companies aren&rsquo;t crazy at all. The acquiring companies must believe that they can utilize AI to quickly convert the profitless potential of their biotech acquisitions into robust profitability.




Essentially, the IBB ETF focuses on <a href="https://investorplace.com/stock-types/blue-chip-stocks/">blue-chip stocks</a>. Eight of its top 10 constituents produce profits, and its largest holdings include firms like Gilead (NASDAQ:<a href="https://investorplace.com/stock-quotes/gild-stock-quote/">GILD</a>), Regeneron (NASDAQ:<a href="https://investorplace.com/stock-quotes/regn-stock-quote/">REGN</a>) and Amgen (NASDAQ:<a href="https://investorplace.com/stock-quotes/amgn-stock-quote/">AMGN</a>). On average, these firms trade at a 22.6x forward P/E ratio, barely above its 10-year average of 19.6x.



Meanwhile, the riskier SPDR S&amp;P Biotech ETF gives greater upside potential. As Eric also notes:




When animal spirits are running hot in the stock market, the speculative XBI portfolio outperforms the relatively conservative IBB portfolio by a wide margin.




That&rsquo;s because the XBI ETF covers more speculative bets. Only one of the top 10 holdings of the XBI portfolio has booked a profit during the last 12 months. And given the stock market&rsquo;s recent rally, it&rsquo;s no surprise that XBI has risen 30%, compared to IBB&rsquo;s more muted 12%.



In either case, he believes that AI-enhanced drug discovery will help revolutionize the economics of drug discovery. Rather than pour millions of dollars into unknown cures, biotech firms may be able to virtually test these therapies first, and advance only the best candidates into human trials.



<h2>The Quant Edge</h2>



The bets you&rsquo;ve just read rely heavily on fundamental research. Insider purchases&hellip; blockbuster drugs&hellip; AI developments&hellip; these are all factors that can change the course of a company.



However, fundamental factors aren&rsquo;t always present. A lull in the biotech industry during 2016 through 2020 left few good options besides the largest firms. And insiders aren&rsquo;t always buying shares of their companies for the right reasons.



As luck would have it, Luke&rsquo;s latest project helps investors overcome this. In his <a href="https://secure.investorplace.com/?cid=MKT793950&amp;eid=MKT798792&amp;step=start&amp;plcid=PLC205880&amp;SNAID=%%SNAID%%&amp;email=%%emailaddr%%&amp;encryptedSnaid=%%ENCRYPTEDSNAID%%&amp;emailjobid=%%jobid%%&amp;emailname=%%emailname_%%">2nd Trillion-Dollar AI Trade</a> summit, he explains why his system is picking out bets that are performing even better than regular breakout stocks. And the timing for this summit couldn&rsquo;t have been better, because a certain change in policy is about to send certain <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> soaring. And thanks to Luke&rsquo;s system, he&rsquo;s been able to identify six stocks that are poised to skyrocket. He put all six of these tiny companies inside a brand-new report called The 6,000% A.I. Biotech Blueprint. <a href="https://secure.investorplace.com/?cid=MKT793950&amp;eid=MKT798792&amp;step=start&amp;plcid=PLC205880&amp;SNAID=%%SNAID%%&amp;email=%%emailaddr%%&amp;encryptedSnaid=%%ENCRYPTEDSNAID%%&amp;emailjobid=%%jobid%%&amp;emailname=%%emailname_%%">Find out how to access it here</a>.



On the date of publication, Thomas Yeung did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Tom Yeung is a market analyst and portfolio manager of the Omnia Portfolio, the highest-tier subscription at InvestorPlace. He is the former editor of Tom Yeung&rsquo;s Profit &amp; Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/5-healthcare-stocks-to-buy-for-2024/">5 Healthcare Stocks to Buy for 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

5 Healthcare Stocks to Buy for 2024

Corbus Pharmaceuticals (CRBP) has shared an update. Corbus Pharmaceuticals Holdings, Inc. has approved new employment agreements for its CEO, Yuval...

Corbus Pharmaceuticals Executives Sign New Employment Deals

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The best <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. 



Regulatory hurdles make finding biotech stocks to buy challenging if you don&rsquo;t have the patience to wait it out.



But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That&rsquo;s why it&rsquo;s a good idea to at least consider biotech, and whether they have a spot in your portfolio.



Biotech stocks represent companies involved in the research, development and commercialization of biological-based products that are designed to improve health. These companies can include pharmaceuticals, biotechnology, medical devices, and healthcare services.



While the industry is challenging because of the regulatory approval process and keen competition, biotech stocks do have some significant advantages. 



For example, they are relatively immune to economic downturns. Even when the economy does poorly, people and insurance companies will spend money on monthly medications they need to improve their quality of life. 



As the population ages, healthcare spending for pharmaceuticals and other medical products will continue to increase.



We&rsquo;re using the Portfolio Grader to find the best biotech stocks to buy in today&rsquo;s market. Each of these stocks gets top grades.



<h2>Eli Lilly &amp; Co. (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div>Weight loss drugs are one of the most popular trends in the biotech industry right now, with an estimated <a href="https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity">42% of the U.S. population</a> considered obese. That&rsquo;s why the first two companies on our list are top picks, both of them are soaring on the strength of their weight loss medications.



The U.S.-based company in this equation is Eli Lilly &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>), which markets its obesity drug under the name Zepbound. About 1 in 3 people who took the injectable drug at its highest dose (15 mg) report losing more than 58 pounds over a 72-week period.



The drug in Zepbound, tirzepatide, is also used in another highly successful Lilly product called Mounjaro, which is used to treat type 2 diabetes. Analysts believe that Zepbound can eventually be worth $25 billion a year in sales, and that Mounjaro sales could jump from $5.2 billion in 2023 to $16 billion in 2024.



<h2>Novo Nordisk (NVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/nvo-stock-300x169.jpg" alt="Novo Nordisk logo on a corporate building"><div>Source: joreks / Shutterstock.com</div></div>The European entry into this equation is Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>), which has an injectable weight loss drug of its own called Wegovy. Wegovy was approved in 2021 in the U.S. to treat obesity and recently expanded to the U.K.



Expansion came with some growing pains, though. Some pharmacies continue to report shortages, and Novo Nordisk <a href="https://www.novonordisk-us.com/supply-update.html">says</a> its running its manufacturing lines 24 hours a day to try to maintain the supply.



Norvo Nordisk also manufactures the drug Ozempic as a treatment for type 2 diabetes, but doctors have also prescribed it as a treatment for weight loss.



NVO saw <a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167013">revenue</a> of $21.4 billion in the fourth quarter, up 31% from the previous year. Profits of $7.7 billion were a 51% increase from the previous year.



NVO stock is up 20% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Corbus Pharmaceuticals (CRBP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/crbp1600-300x169.png" alt="Corbus Pharmaceuticals (CRBP) leads in developing innovative drugs to treat inflammatory and fibrotic diseases. Exceptional quality patient focus"><div>Source: MacroEcon / Shutterstock.com</div></div>Corbus Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) is a Massachusetts-based drugmaker specializing in oncology treatments. The company has potential drugs in its pipeline to treat solid tumors with antibody drug conjugates and monoclonal antibodies.



The most advanced treatment is treating U.S. patients with metastatic urothelial cancer <a href="https://www.corbuspharma.com/press-releases/detail/410/corbus-announces-dosing-of-first-patient-in-u-s-phase-1">in a trial study</a>.



Corbus also started work on a treatment for obesity and related conditions, although trials for that aren&rsquo;t expected to begin until the fourth quarter of this year.



Corbus doesn&rsquo;t have revenue coming in yet, so it&rsquo;s seeing steep losses &ndash; $8 million in the fourth quarter and $44.6 million for the full year. But that&rsquo;s expected for a biotech stock that has drugs in the pipeline but none yet for sale. You have to be willing to ride it out.



Many investors are. CRBP stock is up more than 500% so far this year as the market reacts to positive developments in the company&rsquo;s clinical trials. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Aptorum Group (APM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/apm-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website for Aptorum Group (APM)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Aptorum Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/apm-stock-quote/">APM</a>) is a U.K.-based pharmaceutical company developing oncology and infectious diseases treatments. 



Its approach includes screening approved drug molecules and using its research platform to seek and develop new treatments and therapies.



The company recently agreed to a <a href="https://www.marketwatch.com/story/aptorum-group-to-merge-with-yoov-group-split-off-legacy-assets-28822b75">reverse merger</a> between its wholly owned subsidiary and YOOV Group, specializing in AI techniques to optimize business operations. &nbsp;APM shareholders will own 10% of the combined company after the merger.



Aptorum also plans to split off its legacy business assets into a subsidiary to be called Aptorum Therapeutics.



News of the merger and restructuring turbocharged APM shares, which are now up 264% in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Merck &amp; Co. (MRK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mrk-stock-3-300x169.jpg" alt="Merck (MRK) logo outside of corporate building"><div>Source: Atmosphere1 / Shutterstock.com</div></div>Merck &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/">MRK</a>) is a New Jersey-based pharmaceutical company best known for its Keytruda cancer treatment. Keytruda brought in <a href="https://www.fiercepharma.com/pharma/whos-no-1-25b-sales-mercks-keytruda-appears-set-be-top-selling-drug-2023">$25 billion</a> in sales in 2023, making it the top-selling drug in the world.



But Merck also has many other drugs on the market, including Gardasil for human papillomavirus; ProQuad, which is a vaccine for measles, mumps, rubella and chickenpox; and Januvia for type 2 diabetes. And that&rsquo;s important, as Merck will lose exclusivity for Keytruda in 2028, making it available for generic substitutes.



Merck expanded that pipeline last month by <a href="https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/">completing its acquisition</a> of Harpoon Therapeutics. The company&rsquo;s lead drug candidate treats small cell lung cancer and neuroendocrine tumors.



Earnings for the <a href="https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/">fourth quarter</a> included revenue of $14.6 billion, up 6% from a year ago. The company reported a loss of $1.2 billion and 48 cents per share as part of previously announced charges incurred in its deal with Daiichi Sankyo to jointly develop three cancer treatments.



MRK stock is up 16% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Gyre Therapeutics (GYRE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Gyre Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gyre-stock-quote/">GYRE</a>) is a North Carolina-based biotech company developing treatments for organ fibrosis and inflammatory diseases. 



The company completed a Phase 2 trial in China for its treatment of hepatitis B-induced liver fibrosis.



It&rsquo;s now planning a Phase 2 trial for the treatment in the U.S. The drug candidate, Hydronidone, is a structural analog of pirfenidone, which is already approved in the U.S. and China for the treatment of idiopathic pulmonary fibrosis.



The company says there are more than 140 million people who have liver fibrosis from hepatitis B, with no approved therapies on the market. So, its treatment has the potential to be profitable for investors.



Gyre posted full-year revenue in 2023 of $113.5 million, up from $102.3 million in 2022.



GYRE stock is up 330% in the last 12 months, but has been falling so far in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Neurogene (NGNE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div>Neurogene (NASDAQ:<a href="https://investorplace.com/stock-quotes/ngne-stock-quote/">NGNE</a>) is a biotech company that is developing what it calls EXACT gene therapy technology. 



The platform can be used to achieve optimized levels of transgene expression for each drug candidate, which Neurogene says gives it an advantage over traditional gene therapy.



It&rsquo;s currently working with the platform to develop its lead gene therapy candidate for Rett syndrome, which is a disorder seen in children that impairs their ability to walk, eat, speak or breathe.



The company went public just last year in a <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-closing-merger-neoleukin-therapeutics-and">reverse merger</a> with cancer drug developer Neoleukin Therapeutics backed by investment firms that put $95 million into the newly formed company. The investment is expected to <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-fourth-quarter-and-full-year-2023-financial">assure Neurogene of funding</a> until the second half of 2026.



That gives it a solid window to develop and get approvals.



NGNE stock is up 95% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On the date of publication, Louis Navellier held LLY and NVO. He did not have (either directly or indirectly) any other positions in the securities mentioned in this article.



The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/04/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024/">7 A-Rated Aggressive Biotech Stocks to Bet On in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.



Inflation was moderating and the Federal Reserve was hinting it would cut interest rates at least three times this year. Beginning last October, the performance of the Russell 2000 index of small-cap stocks started pulling away from that of the S&amp;P 500. But it wouldn&rsquo;t last. Runaway government spending drove inflation higher and Fed chairman Jay Powell just intoned he no longer has &ldquo;confidence&rdquo; inflation is heading the right way. That means we won&rsquo;t get interest rate cuts until at least December, according to some analysts.



High interest rates are death to small businesses. Because they rely upon financing to fund their expansion, a rising rate environment absolutely kills the small business market. It&rsquo;s why the Russell 2000 has been such a poor performer these past few years. It could also mean they will continue lagging in 2024.



But not all small companies are underachieving. In fact, some have been market standouts, even beating the likes of top tech headliners like Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) and Super Micro Computer (NASDAQ:<a href="https://investorplace.com/stock-quotes/smci-stock-quote/">SMCI</a>). The three small-cap stocks below are up at least 304% so far this year. Let&rsquo;s see if they can keep running well ahead of the index.



<h2>Dave (DAVE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/01/dave-stock-1-300x169.jpg" alt="The logo for Dave (DAVE) is displayed"><div>Source: Ricky Of The World / Shutterstock.com</div></div>Comedian Steve Martin used to joke that you needed to have a big, strong name for a bank because no one is going to put their money into Fred&rsquo;s Bank. &ldquo;Hi, I&rsquo;m Fred. I have a bank.&rdquo; Well, meet Dave (NASDAQ:<a href="https://investorplace.com/stock-quotes/dave-stock-quote/">DAVE</a>). It&rsquo;s a digital bank, or as it likes to call itself, a neobank. And people are flocking to its services. Operating revenue grew 26% last year and it finally turned profitable in the fourth quarter on an adjusted and GAAP basis.



The primary feature of Dave is its ExtraCash product, which provides small (up to $500) short-term loans without any interest, late fees or credit checks. Essentially Dave is a payday lender but at lower cost. While it doesn&rsquo;t have any of the typical charges that come with a payday loan, it does charge a $1 per month subscription fee and it costs between $3 and $25 to access the loan immediately. There&rsquo;s also the option to tip up to 15% (yeah, tipping culture is way out of hand if you&rsquo;re tipping a bank).&nbsp;



The Los Angeles Times noted the typical payday lender had an <a href="https://www.latimes.com/business/story/2022-05-18/dave-inc-jason-wilk-cash-advance-app">interest rate of 414%</a> if paid back within two weeks. An ExtraCash express loan, with tip, could have an interest rate of between 100% to well over 500%. Dave will also keep withdrawing money from your bank account until the loan is fully paid back.



Dave has <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1841408/000095017024026024/dave-20231231.htm">over 13 million registered members</a>, 10 million of whom have used at least one product. It added over 680,000 new members in the fourth quarter. The stock is up 304% in 2024. While it&rsquo;s not a particularly good financial solution, Dave stock could go even higher as cash-tight consumers turn to alternative funding sources.



<h2>Corbus Pharmaceuticals Holdings (CRBP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/crbp1600-300x169.png" alt="Corbus Pharmaceuticals (CRBP) leads in developing innovative drugs to treat inflammatory and fibrotic diseases. Exceptional quality patient focus"><div>Source: MacroEcon / Shutterstock.com</div></div>Oncology biotech Corbus Pharmaceuticals Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) was bouncing along the $5 per share range for months on end until this past January when it reported results from an early-phase trial for its antibody-drug conjugate (ADC) CRB-701. Following the report, Corbus&rsquo; stock quadrupled in value and today is up 515%.



What likely got investors excited was the news stoked the fires of a potential acquisition. Not that Corbus has received any offers, but there have been numerous acquisitions in the space of late. Just this year Bristol-Myers Squibb (NYSE:<a href="https://investorplace.com/stock-quotes/bmy-stock-quote/">BMY</a>) paid $800 million upfront to China&rsquo;s SystImmune as part of a <a href="https://www.fiercebiotech.com/biotech/bristol-myers-pays-800m-upfront-antibody-drug-conjugate-opening-new-front-merck-co-rivalry">deal for its ADC worth up to $8.4 billion</a>; AbbVie (Nasdaq: <a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>) acquired ImmunoGen for $10 billion and Johnson &amp; Johnson (NYSE:<a href="https://investorplace.com/stock-quotes/jnj-stock-quote/">JNJ</a>) bought Ambrx Biopharma for $2 billion.



Yet investors might be getting ahead of themselves. Those deals for ADCs were much further along the path than is CRB-701. For example, AbbVie got ImmunoGen&rsquo;s ADC (which is <a href="https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen">FDA-approved</a>) but also the rest of its oncology portfolio, too. Johnson &amp; Johnson <a href="https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-ambrx-advancing-next-generation-antibody-drug-conjugates-to-transform-the-treatment-of-cancer">acquired numerous ADCs</a> in the Ambrx deal.



There is potential for Corbus Pharmaceuticals to advance early but a 500% gain for such an early stage development seems like putting the cart before the horse. It does have <a href="https://investorplace.com/market360/2024/04/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024/">other drugs under development</a> too, but I still see the biotech&rsquo;s shares retreating at some point.



<h2>Skye Bioscience (SKYE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Skye Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/skye-stock-quote/">SKYE</a>) is another biotech bounding higher this year on <a href="https://investorplace.com/2024/04/these-3-biotech-stocks-are-up-269-in-2024-is-there-more-to-come/">good, early phase news</a>, though its drug candidate is further along in the clinical-trial stage. The biotech announced in February it had completed enrollment in a phase 2A study for its glaucoma drug SBI-100 Ophthalmic Emulsion (OE). It had targeted 54 patients for the study but got 56 enrolled and did it sooner than expected. It is now expecting topline data to be reported sometime in the second quarter.



Previously, Skye <a href="https://ir.skyebioscience.com/news-events/press-releases/detail/186/skye-bioscience-receives-ind-clearance-for-phase-2-clinical">received clearance</a> for its Investigational New Drug (IND) application with the Food &amp; Drug Administration to begin phase 2 trials of nimacimab, a therapy for patients with obesity and chronic kidney disease.



All the positive news sent Skye Biopharma stock rocketing higher. It used the higher share price to raise $40 million in equity financing, which set the stock back a bit. However, it was able to also move the stock from the over-the-counter pink sheets to the Nasdaq exchange, which sent the stock jumping again. Today it 535% above the price it started 2024 at.



On the date of publication, Rich Duprey held a LONG position in ABBV and JNJ stock. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher/">These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?

Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology

ABBV

ACAD

ADCT

AMGN

CRSP

ELEV

GILD

GYRE

MSFT

NGNE

NTLA

NVCT

REGN

SDGR

SEZL

SKYE

SMCI

Press Releases

Corbus Pharmaceuticals Announces Proposed Public Offering

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Management

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting